Medication Adherence and Outcomes Among Patients in United States With HIV (CHANGE)
Human Immunodeficiency Virus, Medication Adherence
About this trial
This is an interventional treatment trial for Human Immunodeficiency Virus
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of HIV, established in 2017 or earlier
- Patients at least 18 years of age or older
- Currently prescribed first or second line ART medications
- Non-suppressed viral loads, with two consecutive non-suppressed viral loads (VL>400 copies/ml) for the past two lab readings.
Exclusion Criteria:
- Pregnant
- Prescribed Maraviroc or Fuzeon
- More than 5 additional medications
- Diagnosed with insulin dependent diabetes
- Unable to provide consent
- Non-English speaker
- Cognitive impairment, per PI discretion
- Does not have stable residence
Sites / Locations
- Drexel University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
adherence based financial incentives
control
Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.